Biolidics issues letter of demand to biochip partner Sysmex over IP matters
Singapore
A CATALIST-LISTED medtech firm that made strong gains this year as investors hunted for exposure to tech plays and Covid-19 test makers, has now claimed that a Japanese group breached intellectual property-related (IP) agreements.
Biolidics has issued a letter of demand to Japan-based healthcare group Sysmex Corporation, saying that Sysmex breached IP obligations under a collaboration agreement struck in 2016 for the joint development of biochips.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
ExxonMobil sees Hess arbitration dragging into 2025, CEO says
Gold prices tick higher on US rate cut bets
Nomura targets 20% revenue growth from global markets business
FLCT posts 1.1% lower H1 DPU of S$0.0348 on higher vacancies, expenses
Singapore shares rise at Tuesday’s open tracking global rally; STI up 0.2%
Segantii allegations roil a go-to block trader for global banks